ALN-F1202
Phase 1Small molecule
RegeneronALN-F1202 is one of 32 small molecule programs targeting Phase 1. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
59 competitors in Phase 1
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Fludara
SanofiPhase 2
Venclexta
AbbViePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Erbitux
IImclone
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Navitoclax
AbbViePhase 2
Yervoy
Bristol-Myers SquibbPhase 1
Benznidazole
CCorestemchemon, Inc.
Phase 1
VX-407
Vertex PharmaceuticalsPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALN-F1202. EMBL-EBI & Wellcome Sanger Institute.
- [4]